News Hanall Biopharma Co., Ltd.

Equities

A009420

KR7009420001

End-of-day quote Korea S.E. Other stock markets 03:30:00 17/05/2024 am IST			5-day change	1st Jan Change
37,300 ^KRW	+2.05%		+9.06%	-15.80%

03/05	HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease	CI
06/03	Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease	03/05	CI
Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
Vincere Biosciences announces strategic investment from Daewoong Pharmaceutical and HanAll Biopharma to foster collaboration	13/23/13	AQ
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson's disease	13/23/13	AQ
Vincere Biosciences Inc announced that it has received funding from Hanall Biopharma Co., Ltd., Daewoong pharmaceutical Co.,Ltd	12/23/12	CI
Hanall Biopharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update	01/23/01	AQ
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth	30/23/30	AQ
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program	16/23/16	AQ
HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities	13/23/13	AQ
Interon Laboratories, Inc. announced that it has received funding from Hanall Biopharma Co., Ltd.	13/23/13	CI
Interon Laboratories, Inc. announced that it expects to receive funding from Hanall Biopharma Co., Ltd.	10/23/10	CI
Immune Thrombocytopenia Pipeline as Novel and Extensive 30+ Therapies Likely to Enter in the Treatment Domain	09/22/09	AQ
HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update	16/22/16	AQ
HanAll Biopharma's Licensed Partner in China Provides Updates on Phase 3 Trial in Dry Eye Disease in China	11/22/11	AQ
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab	11/22/11	CI
Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner	04/22/04	CI
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update	01/22/01	AQ
Hanall Biopharma : Decision on Disposal of Treasury Stock	23/22/23	PU
Tranche Update on Hanall Biopharma Co.,Ltd's Equity Buyback Plan announced on March 10, 2022.	15/22/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Hanall Biopharma Co., Ltd.

Equities

A009420

KR7009420001

Summary

Filters